JORGE E MENDIA M.D.
Prescription History 1982609178
Obstetrics & Gynecology in Miami, FL

NPI Status: Active since June 15, 2005

Contact Information

3659 S MIAMI AVE
STE 5005
MIAMI, FL
ZIP 33133
Phone: (305) 854-2899
Fax: (305) 859-9677

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JORGE E MENDIA M.D., an active Obstetrics & Gynecology specialist practicing in Miami, FL. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 64 documented patient claims. Among these therapy options, the most frequently utilized medication is Clotrimazole-Betamethasone, which accounts for 23 claims alone.

Medication Index

No matching medications currently found on file.

Clotrimazole-Betamethasone

Generic Formulation: Clotrimazole/Betamethasone DipSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 324
FL State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills36.4
Peer Average Days Supply846
Conservative Utilization

This provider writes prescriptions for this formulation 32.4% less frequently than the standard regional baseline metric for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $355.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.44

State Avg Cost Per Claim

$28.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. This product contains 2 medications. Clotrimazole is an azole antifungal that works by preventing the growth of fungus. Betamethasone is a strong corticosteroid that works by reducing the swelling, redness, and itching that occurs in the skin infection. This medication is not recommended for children younger than 17 years or for diaper rash.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 16
30-Day Fills 35.8
Days Supply 1,068
FL State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills91.5
Peer Average Days Supply2,735
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $775.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.45

State Avg Cost Per Claim

$70.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 55
FL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply274
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $118.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.81

State Avg Cost Per Claim

$23.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Yuvafem

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 37.0
Days Supply 1,108
FL State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills35.5
Peer Average Days Supply1,049
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across FL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,455.49 across this reporting matrix range.

Provider Avg Cost Per Claim

$175.39

State Avg Cost Per Claim

$167.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JORGE E MENDIA M.D. provides transparency into local medical care patterns within Miami, FL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.